Drugs that curb appetites could also curb the world’s demand for farmland. Widespread, sustained use of GLP-1 medications for obesity would leave more land outside agriculture by 2050 than a future without that expansion, a computer simulation suggests.

Peter Alexander, a global food systems researcher at the University of Edinburgh in Scotland, and coauthors report the findings November 19 in Nature Communications. Their model followed how reduced food demand would affect prices, trade, crop production and land use.

The team compared treatment expanding across wealthy countries, wealthier and middle-income countries, or the entire world. In each case, the model progressively reduced food consumption among adults with obesity and assumed the reduction persisted.

With worldwide uptake, reduced calorie consumption alone left about 32 million hectares, or 79 million acres, more land outside crops, pasture and managed forests than in the comparison scenario. Adding a shift toward diets richer in plants and lower in meat and sugar raised that difference to about 46 million hectares, or 114 million acres. These figures describe less land conversion or more recovery relative to the comparison future, not necessarily an increase over today’s natural land.

Lower demand also brought lower food prices. That made food more affordable, but introduced a catch for people not taking the drugs. “Lower prices and shifting demand may drive increased consumption of meat and sugar,” the researchers write. That rebound partially offset the modeled health benefits.

The results are possibilities, not forecasts. The simulations assume broad access and sustained appetite suppression; costs, treatment discontinuation and weight regain could substantially reduce the effects. The healthier eating pattern was an added assumption, not an established consequence of taking GLP-1 drugs.

Nor does less agricultural land automatically mean restored wildlife habitat. The study did not assess habitat quality or calculate greenhouse gas emissions, including those from manufacturing the medications.

The research

Impacts of medications for obesity on global health and the environment ↗

Roslyn C. Henry, Lindsay M. Jaacks, Kaia Waxenberg and Peter Alexander

Nature Communications · Published

DOI: 10.1038/s41467-026-79412-w

Subscribe to our newsletter to get In Touch with Science . . . in your email!